Slingshot Insights

Catalyst

Slingshot members are tracking this event:

Phase 2 study of GS-4774 in Combination With Tenofovir Disoproxil Fumarate (TDF) for the treatment of Chronic HBV to complete June 2018

Source Link:: https://www.clinicaltrials.gov/ct2/show/NCT02174276?term=gs-4774&rank=2

Do you think this event is important to the companies below? How will it affect their stock price?

Related Companies

Importance

High

Medium

Low

Impact on Stocks

GILD

100%

GBIM

66%

SIGN ME UP
I want to vote! LOG ME IN
Now!

Additional Information

Additional Relevant Details "the GS-4774 Phase 2 clinical trial in patients with chronic HBV infection who are currently not receiving treatment, is fully enrolled and the 48-week results are projected to be available in the second half of 2016"

https://www.globeimm...

Additional Relevant Details The Phase 2 study of GS-4774 on the treatment of chronic hepatitis B in combination with tenofovir disoproxil fumarate (TDF) is expected to complete in March 2016. Expect primary data to be released within 30 days after the completion of the study. The study, by GlobalImmune (commercial rights Gilead Sciences), aims to measure mean change in serum hepatitis B surface antigen (HBsAg) from baseline to Week 24.

https://www.clinical...

Additional Relevant Details Update on 11,4,2016: Initially expected to complete in March 2016, it the completion date is expected in June 2018.

https://www.clinical...

Slingshot Insights Explained

JOIN FOR FREE TODAY

Catalyst Date

Occurred on:

Jun 15, 2018

Occurred Source:

https://www.clinicaltrials.gov/ct2/show/NCT02174276?term=gs-4774

Related Projects

Don’t see a project related to the catalyst you care about?

Related Keywords Gs-4774, Chronic Hepatitis B, Phase 2 Study